Tokio Marine Asset Management Co. Ltd. Purchases New Stake in Olink Holding AB (publ) (NASDAQ:OLK)

Tokio Marine Asset Management Co. Ltd. purchased a new stake in Olink Holding AB (publ) (NASDAQ:OLK) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 665,400 shares of the company’s stock, valued at approximately $16,735,000. Olink Holding AB (publ) makes up about 0.9% of Tokio Marine Asset Management Co. Ltd.’s investment portfolio, making the stock its 28th biggest holding. Tokio Marine Asset Management Co. Ltd. owned about 0.54% of Olink Holding AB (publ) at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jump Financial LLC acquired a new position in shares of Olink Holding AB (publ) in the third quarter valued at approximately $232,000. Wolverine Asset Management LLC acquired a new position in shares of Olink Holding AB (publ) in the fourth quarter valued at approximately $692,000. Trexquant Investment LP increased its stake in shares of Olink Holding AB (publ) by 23.0% in the third quarter. Trexquant Investment LP now owns 33,156 shares of the company’s stock valued at $489,000 after buying an additional 6,193 shares during the period. New York State Common Retirement Fund increased its stake in shares of Olink Holding AB (publ) by 3.7% in the third quarter. New York State Common Retirement Fund now owns 67,166 shares of the company’s stock valued at $991,000 after buying an additional 2,368 shares during the period. Finally, TD Asset Management Inc increased its stake in shares of Olink Holding AB (publ) by 73.7% in the third quarter. TD Asset Management Inc now owns 403,924 shares of the company’s stock valued at $5,958,000 after buying an additional 171,395 shares during the period. Institutional investors and hedge funds own 30.19% of the company’s stock.

Olink Holding AB (publ) Stock Performance

Shares of OLK stock traded up $0.23 during trading hours on Wednesday, hitting $22.43. 244,287 shares of the company were exchanged, compared to its average volume of 678,886. The firm has a market cap of $2.79 billion, a P/E ratio of -89.72 and a beta of 0.50. Olink Holding AB has a fifty-two week low of $14.10 and a fifty-two week high of $26.01. The company has a 50 day simple moving average of $23.24 and a two-hundred day simple moving average of $24.07.

Olink Holding AB (publ) (NASDAQ:OLK) last issued its earnings results on Monday, March 25th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.20). Olink Holding AB (publ) had a negative return on equity of 6.50% and a negative net margin of 18.63%. The firm had revenue of $68.55 million during the quarter, compared to the consensus estimate of $82.80 million. As a group, sell-side analysts expect that Olink Holding AB will post -0.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Morgan Stanley reaffirmed an “equal weight” rating and issued a $26.00 price objective on shares of Olink Holding AB (publ) in a research note on Tuesday, March 26th. Canaccord Genuity Group reissued a “hold” rating and set a $26.00 target price on shares of Olink Holding AB (publ) in a research report on Tuesday, March 26th.

Olink Holding AB (publ) Profile

Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on.